The Cooper Companies, based in San Ramon, California, employs 15,000 and operates through CooperVision, focused on contact lenses, and CooperSurgical, specializing in fertility and women's health solutions.
Based on our analysis, Cooper Companies has received a fairly valued rating of 2 out of 5 stars from Cashu, indicating that the stock may not present a compelling investment opportunity at its current price. Several financial ratios highlight areas where Cooper Companies does not outperform its sector, suggesting potential concerns for investors.
One key ratio is the Price-to-Earnings (PE) Ratio, which stands at 49.12, significantly higher than the sector average of 15.21. This implies that investors are paying a premium for each dollar of earnings, which could indicate overvaluation or high growth expectations that may not be met.
Additionally, Cooper Companies' Return on Equity (ROE) is 4.85, compared to a sector average of -74.69. While a positive ROE reflects the company's ability to generate profit from shareholders' equity, the low figure suggests that the company is not efficiently using its equity base to generate returns relative to its peers.
Furthermore, the company has a Dividend Yield of 0.00, while the sector averages at 0.25. This absence of dividends may be a disadvantage for income-seeking investors and reflects a lack of cash returned to shareholders.
In conclusion, while Cooper Companies shows some positive metrics, the high PE ratio, low ROE, and absence of dividend payments point to concerns about its current valuation.
This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued
More Signals
Feature in Progress
This section is under development. Check back soon for updates!